These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 21053991)

  • 1. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation.
    Faessel HM; Obach RS; Rollema H; Ravva P; Williams KE; Burstein AH
    Clin Pharmacokinet; 2010 Dec; 49(12):799-816. PubMed ID: 21053991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Faessel H; Ravva P; Williams K
    Clin Ther; 2009 Jan; 31(1):177-89. PubMed ID: 19243716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.
    Kikkawa H; Maruyama N; Fujimoto Y; Hasunuma T
    J Clin Pharmacol; 2011 Apr; 51(4):527-37. PubMed ID: 20551220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varenicline: a novel pharmacotherapy for smoking cessation.
    Jiménez-Ruiz C; Berlin I; Hering T
    Drugs; 2009 Jul; 69(10):1319-38. PubMed ID: 19583451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.
    Faessel HM; Smith BJ; Gibbs MA; Gobey JS; Clark DJ; Burstein AH
    J Clin Pharmacol; 2006 Sep; 46(9):991-8. PubMed ID: 16920893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers.
    Xiao Y; Lv Y; Zhang X; Guo Y; Bergstrom T
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):246-54. PubMed ID: 19356390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM; Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic analysis of varenicline in adult smokers.
    Ravva P; Gastonguay MR; Tensfeldt TG; Faessel HM
    Br J Clin Pharmacol; 2009 Nov; 68(5):669-81. PubMed ID: 19916991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
    Faessel HM; Gibbs MA; Clark DJ; Rohrbacher K; Stolar M; Burstein AH
    J Clin Pharmacol; 2006 Dec; 46(12):1439-48. PubMed ID: 17101743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers.
    Zhao Q; Schwam E; Fullerton T; O'Gorman M; Burstein AH
    J Clin Pharmacol; 2011 Apr; 51(4):492-501. PubMed ID: 20466870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.
    Cui Q; Robinson L; Elston D; Smaill F; Cohen J; Quan C; McFarland N; Thabane L; McIvor A; Zeidler J; Smieja M
    AIDS Patient Care STDS; 2012 Jan; 26(1):12-9. PubMed ID: 22007690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral varenicline for smoking cessation.
    Zierler-Brown SL; Kyle JA
    Ann Pharmacother; 2007 Jan; 41(1):95-9. PubMed ID: 17190845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.
    Ravva P; Gastonguay MR; Faessel HM; Lee TC; Niaura R
    Nicotine Tob Res; 2015 Jan; 17(1):106-13. PubMed ID: 25145377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers.
    Burstein AH; Fullerton T; Clark DJ; Faessel HM
    J Clin Pharmacol; 2006 Nov; 46(11):1234-40. PubMed ID: 17050788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S
    J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.